AbstractAim: The purpose of this investigation was to examine bone mineral density (BMD) in patients with PsA as measured by dualenergy X-ray absorptiometry at the hip and lumbar spine.
Methods: 20 patients with PsA were recruited in succession and evaluated for osteoporosis. A comprehensive data collection effort was undertaken, encompassing demographic information as well as indicators of disease activity and health status.
Results: The range of PsA patients was 18 to 70 years, with a mean age of 53.4 ± 9.3 years. Among them, 61 (50.8%) were females and 59 (49.1%) were males. The mean height was 168.0 cm and the mean weight was 81.9 kg. The average duration of the disease was 6.8 years. Mean CRP levels were 2.2, and ESR was 15. Corticosteroids applied topically were utilized by 43% of patients with PsA. Current NSAID use was reported by 34 patients, synthetic DMARD use was reported by 76 patients, and calcium and vitamin D supplement use was reported by 16 patients. Comparable to the expected value of 16%, the proportion of patients with insufficient BMD was ascertained using the normal distribution of the Z score within the population. An incidence of osteoporosis was a mere 6.4% among the patients. There were no statistically significant correlations observed between BMD and disease activity measures.
Conclusion: PsA patients exhibited a low prevalence of osteoporosis or poor BMD, which was comparable to the range observed in the reference population. This suggests that, relative to the general population, patients with PsA do not have an elevated risk of developing osteoporosis. As a result, clinicians may apply the same osteoporosis monitoring guidelines for patients with PsA as they would for the general population.
